Biotech | March 10, 2022
Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Women's health is in fact a direct reflection of the nation's overall health
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy
Subscribe To Our Newsletter & Stay Updated
